Expand MOLN Menu
MOLN MENU

MOLN Latest Press Releases

-- July 16, 2026 --

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma Globe Newswire 1:00 AM

-- July 15, 2026 --

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference Globe Newswire 1:00 AM

-- July 6, 2026 --

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics Globe Newswire 1:00 AM

-- July 2, 2026 --

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 Globe Newswire 1:00 AM

-- May 30, 2026 --

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 Globe Newswire 8:00 AM

-- May 26, 2026 --

Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit Globe Newswire 4:00 PM

-- May 12, 2026 --

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 Globe Newswire 4:00 PM

-- May 4, 2026 --

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences Globe Newswire 1:00 AM

-- May 1, 2026 --

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling Globe Newswire 7:00 AM

-- April 19, 2026 --

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 Globe Newswire 12:00 PM

-- April 14, 2026 --

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting Globe Newswire 4:00 PM
Market Data Delayed 15 Minutes